Influence of amorphous nanosilica on the parameters of multiparametric ultrasound investigation in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease

Main Article Content

P.M. Воdnar
N.A. Marunchyn
O.B. Dynnyk
E.P. Voronin
L.M Osynnia


Background. The purpose of this study was to evaluate the influence of amorphous nanosilica on the indices of multiparametric ultrasound investigation in patients with type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD). Materials and methods. The research was conducted in Kyiv endocrine centre in 2015–2017. Simultaneous abdominal ultrasound was made in all 105 patients on Soneus P7 device (Ultrasign, Ukraine) and included В-mode, dopplerography (-metry), strain and share wave elastography (-metry), steatography (-metry) with attenuation coefficient measurement to evaluate the effectiveness of treatment. We used amorphous nanosilica in suspension for the treatment of NAFLD. Results. There was found a decrease in the data of the right liver lobe elastography and its size, blood flow velocity of portal vein in the treatment group. Besides, there was also proved the reduction of progression of right lobe liver stiffness, size of the right and left liver lobes, the diameter and blood flow velocity of portal vein in the treatment group. Conclusions. The amorphous nanosilica can be recommended for the treatment of NAFLD in patients with T2DM, because it has hepatoprotective effect due to decrease in the data of right liver lobe elastography and its size, blood flow velocity of portal vein and the reduced progression of right lobe liver stiffness, size of right and left liver lobes, the diameter and blood flow velocity of portal vein.

Article Details

How to Cite
Воdnar P., N. Marunchyn, O. Dynnyk, E. Voronin, and L. Osynnia. “Influence of Amorphous Nanosilica on the Parameters of Multiparametric Ultrasound Investigation in patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 13, no. 3, June 2017, pp. 150-6, doi:10.22141/2224-0721.13.3.2017.104111.
Original Researches


EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388-402. doi: 10.1016/j.jhep.2015.11.004.

Kobyliak N, Dynnyk O, Kyriienko D. Current approaches to the diagnosis and screening for metabolic disorders in patients with nonalcoholic fatty liver disease. Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2015;5(69):89-99. (In Ukrainian). doi: 10.22141/2224-0721.5.69.2015.75179.

Mazzella N, Ricciardi LM, Mazzotti A, Marchesini G. The role of medications for the management of patients with NAFLD. Clin Liver Dis. 2014;18(1):73-89. doi: 10.1016/j.cld.2013.09.005.

Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol. 2015;62(1 Suppl):65-75. doi: 10.1016/j.jhep.2015.02.041.

Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643-54. PMID: 24768810. doi: 10.1016/j.cgh.2014.04.014.

Hafliddadotir S, Jonasson JG, Norland H, Einarsdottir SO, Kleiner DE, Lund SH, et al. Long-term follow up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol. 2014 Sep 27;14:166. PMID: 25260964. doi: 10.1186/1471-230X-14-166. 

Chuyko A, Tiortykh VA, Lobanov VV, authors. Struktura i fiziko-himicheskie svojstva poverhnosti kremnezema [Structure and physics and chemical properties of surface kremnezem]. In: Chuyko A, editor. Medicinskaja himija i klinicheskoe primenenie dioksida kremnija [Medical chemistry and clinical application of silicon dioxide]. Kyiv; 2003. pp. 10-286. (In Russian).

Voronin E. Creation of stable dispersion of nanokremnezem as sorbptional and detoxication methods of medical appointment. Poverhnyst. 2016;8(23):267-283. (In Ukrainian).

Bodnar P, Donysh R. Therapeutic effect of enterosorption in diabetes mellitus. Klinicheskaja medicina. 1988;7:62-4. (In Russian).

Sadyk A.I. Jaradat. Practice of using of Silica in treatment of liver steatosis in patients with type 2 diabetes mellitus. Nauchnyj vestnik nacional'nogo medicinskogo universiteta imeni A.A. Bogomol'ca. 2007;2-3:91-3. (In Ukrainian).

Hamaguchi M, Kojima T, Itoh Y, et al. The Severity of Ultrasonographic Findings in Nonalcoholic Fatty Liver Disease Reects the Metabolic Syndrome and Visceral Fat. American J Gastroenterol. 2007;102:2708-15. PMID: 17894848. doi: 10.1111/j.1572-0241.2007.01526.x.

Chauhan A, Sultan RL, Furth EE , et al. Diagnostic accuracy of hepatorenal index in the detection and grading of hepatic steatosis. J Clin Ultrasound. 2016 Nov;44(9):580-6. PMID: 27447717. doi: 10.1002/jcu.22382.

Sasso M., Tengher-Barna I., Ziol M. et al. Novel Controlled Attenuation Parameter (CAP™) for non-invasive assessment of steatosis using FibroScan®: validation in chronic hepatitis C. J Viral Hepatitis. 2011;19:224-53. doi: 10.1111/j.1365-2893.2011.01534.x. Epub 2011 Oct 13.

Stern C, Castera L. Noninvasive diagnosis of hepatic steatosis. Hepatol International. 2017;11(1):70-8. PMID: 27783208. doi: 10.1007/s12072-016-9772-z.

Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48:835-47. PMID: 18334275. doi: 10.1016/j.jhep.2008.02.008.

European Association for the Study of the Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015 Jul;63:237-64. doi: 10.1016/j.jhep.2015.04.006. Epub 2015 Apr 21.

Ferraioli G, Filice C, Castera L, et al. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: liver. Ultrasound Med Biol. 2015 May;41(5):1161-79. doi: 10.1016/j.ultrasmedbio.2015.03.007. Epub 2015 Mar 20.

Heraschenko I. Enterosorbenti: lіkars'kі zasobi і dієtichnі dobavki [Enterosorptions: medical drugs and dietary supplements]. Kyiv: NAN Ukrainian, Chujko Institute of Surface Chemistry; 2014. 250 p. (In Ukrainian).

Nikolaev V, Hurina N. Sorption materials and mechanisms of actions. Klіnіchna eferentologіja. 2010;4:10-45. (In Ukrainian).

Zak K, Tronko N, Popova V, Butenko A, authors. Gormony zhirovoj tkani (adipocitokiny) i saharnyj diabet: sovremennye predstavlenija o roli citokinov v patogeneze saharnogo diabeta 2-go tipa [Hormones of adipose tissue (adypocytokines) in diabetes mellitus: comprehensive conception about the role of cytokines in pathogenesis in type 2 diabetes mellitus]. Zak K, editor. Immunitet. Citokiny [Diabetes mellitus. Immunity. Cytokines]. Kyiv, 2015. pp. 402-6. (In Russian).